Skip to main content
Premium Trial:

Request an Annual Quote

SurroMed Renews Biomarker Collaboration with Merck

NEW YORK, July 7 (GenomeWeb News) - SurroMed has renewed a previously undisclosed biomarker research agreement with Merck, the company said today.

 

SurroMed, based in Menlo Park, Calif., will analyze preclinical samples provided by Merck using its proteomics platform, and will analyze the data to identify candidate biological markers using its informatics tools.

 

The company's other biomarker collaborations include Biogen, Bruker Daltonics, PPD, InterMune, and Eli Lilly.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.